NGM Bio is a clinical stage biopharmaceutical company that develops biologic drugs for the treatment of cardio-metabolic and liver disease.
Read moreAnnual Revenue
$77.9M
NGM Bio's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 4.5B. Over the last four quarters, NGM Bio's revenue has decreased by 2.9%. Specifically, in Q4 2021's revenue was $21M; in Q3 2021, it was $18.6M; in Q2 2021, it was $16.8M; in Q1 2021, NGM Bio's revenue was $21.6M.